Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Dec;28(6):683–694. doi: 10.1111/j.1365-2125.1989.tb03561.x

Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

T M MacDonald 1, K Craig 1, M L Watson 1
PMCID: PMC1380039  PMID: 2532921

Abstract

1. The acute effects of intravenous frusemide (30 mg) on prostaglandin dependent renal haemodynamics, urinary prostaglandin excretion, urinary dopamine excretion and electrolyte excretion were studied in six salt replete healthy volunteers with and without pretreatment with the angiotensin converting enzyme (ACE) inhibitor, ramipril (5 mg) and compared with the effects of ramipril alone in order to clarify the role of the renin-angiotensin system in these responses. 2. Frusemide increased natriuresis (UNaV), kaliuresis (UKV), inulin clearance and plasma renin activity (PRA) and ramipril pretreatment significantly enhanced these effects suggesting that the acute generation of angiotensin II (AII) may attenuate these actions of intravenous frusemide. 3. Frusemide increased para-aminohippurate (PAH) clearance, osmolar clearance and urine flow but did not change filtration fraction or urinary kallikrein excretion. Pretreatment with ramipril did not affect these responses. 4. Frusemide increased the excretion of urinary PGE2 and 6-keto-PGF1 alpha. Ramipril pretreatment did not suppress this rise in prostaglandin excretion. Since the frusemide induced prostaglandin dependent renal haemodynamic changes were also not suppressed with ACE inhibition, this suggests that in salt-replete volunteers AII does not significantly modulate renal prostaglandin production after frusemide. 5. Urinary free dopamine excretion increased with frusemide alone. With ramipril pretreatment this rise showed a tendency to increase. AII may therefore inhibit the rise in urinary dopamine excretion after frusemide. However this requires further study.

Full text

PDF
683

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANTON A. H., SAYRE D. F. THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL. J Pharmacol Exp Ther. 1964 Sep;145:326–336. [PubMed] [Google Scholar]
  2. Abe K., Irokawa N., Yasujima M., Seino M., Chiba S., Sakurai Y., Yoshinaga K., Saito T. The kallikrein-kinin system and prostaglandins in the kidney: their relation to forosemide-induced diuresis and to the renin-angiotensin-aldosterone system in man. Circ Res. 1978 Aug;43(2):254–260. doi: 10.1161/01.res.43.2.254. [DOI] [PubMed] [Google Scholar]
  3. Aiken J. W., Vane J. R. Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther. 1973 Mar;184(3):678–687. [PubMed] [Google Scholar]
  4. Amundsen E., Putter J., Friberger P., Knos M., Larsbraten M., Claeson G. Methods for the determination of glandular kallikrein by means of a chromogenic tripeptide substrate. Adv Exp Med Biol. 1979;120A:83–95. doi: 10.1007/978-1-4757-0926-1_9. [DOI] [PubMed] [Google Scholar]
  5. Ball S. G., Oats N. S., Lee M. R. Urinary dopamine in man and rat: effects of inorganic salts on dopamine excretion. Clin Sci Mol Med. 1978 Aug;55(2):167–173. doi: 10.1042/cs0550167. [DOI] [PubMed] [Google Scholar]
  6. Barnett R., Singhal P. C., Scharschmidt L. A., Schlondorff D. Dopamine attenuates the contractile response to angiotensin II in isolated rat glomeruli and cultured mesangial cells. Circ Res. 1986 Nov;59(5):529–533. doi: 10.1161/01.res.59.5.529. [DOI] [PubMed] [Google Scholar]
  7. Bello-Reuss E., Higashi Y., Kaneda Y. Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule. Am J Physiol. 1982 Jun;242(6):F634–F640. doi: 10.1152/ajprenal.1982.242.6.F634. [DOI] [PubMed] [Google Scholar]
  8. Bussien J. P., Nussberger J., Porchet M., Waeber B., Brunner H. R., Perisic M., Tansey M. J., Bomm M., Hajdu P. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers. Naunyn Schmiedebergs Arch Pharmacol. 1985 Mar;329(1):63–69. doi: 10.1007/BF00695194. [DOI] [PubMed] [Google Scholar]
  9. Bönner G., Beck D., Deeg M., Marin-Grez M., Gross F. Effects of frusemide on the renal kallikrein-kinin system of the rat. Clin Sci (Lond) 1982 Nov;63(5):447–453. doi: 10.1042/cs0630447. [DOI] [PubMed] [Google Scholar]
  10. Ciabattoni G., Pugliese F., Cinotti G. A., Stirati G., Ronci R., Castrucci G., Pierucci A., Patrono C. Characterization of furosemide-induced activation of the renal prostaglandin system. Eur J Pharmacol. 1979 Dec 7;60(2-3):181–187. doi: 10.1016/0014-2999(79)90217-6. [DOI] [PubMed] [Google Scholar]
  11. Clappison B. H., Anderson W. P., Johnston C. I. Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition. Kidney Int. 1981 Nov;20(5):615–620. doi: 10.1038/ki.1981.184. [DOI] [PubMed] [Google Scholar]
  12. Dawborn J. K. Application of Heyrovsky's inulin method to automatic analysis. Clin Chim Acta. 1965 Jul;12(1):63–66. doi: 10.1016/0009-8981(65)90109-9. [DOI] [PubMed] [Google Scholar]
  13. Dunn M. J., Scharschmidt L. A. Prostaglandins modulate the glomerular actions of angiotensin II. Kidney Int Suppl. 1987 May;20:S95–101. [PubMed] [Google Scholar]
  14. Eckert H. G., Badian M. J., Gantz D., Kellner H. M., Volz M. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittelforschung. 1984;34(10B):1435–1447. [PubMed] [Google Scholar]
  15. Felder R. A., Blecher M., Calcagno P. L., Jose P. A. Dopamine receptors in the proximal tubule of the rabbit. Am J Physiol. 1984 Sep;247(3 Pt 2):F499–F505. doi: 10.1152/ajprenal.1984.247.3.F499. [DOI] [PubMed] [Google Scholar]
  16. Frölich J. C., Wilson T. W., Sweetman B. J., Smigel M., Nies A. S., Carr K., Watson J. T., Oates J. A. Urinary prostaglandins. Identification and origin. J Clin Invest. 1975 Apr;55(4):763–770. doi: 10.1172/JCI107987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fülgraff G., Brandenbusch G., Heintze K. Dose response relation of the renal effects of PGA1, PGE2, and PGF-2alpha--in dogs. Prostaglandins. 1974 Oct 10;8(1):21–30. doi: 10.1016/0090-6980(74)90033-1. [DOI] [PubMed] [Google Scholar]
  18. HARVEY R. B., BROTHERS A. J. Renal extraction of para-aminohippurate and creatinine measured by continuous in vivo sampling of arterial and renal-vein blood. Ann N Y Acad Sci. 1962 Oct 31;102:46–54. doi: 10.1111/j.1749-6632.1962.tb13624.x. [DOI] [PubMed] [Google Scholar]
  19. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  20. Hagege J., Richet G. Proximal tubule dopamine histofluorescence in renal slices incubated with L-dopa. Kidney Int. 1985 Jan;27(1):3–8. doi: 10.1038/ki.1985.2. [DOI] [PubMed] [Google Scholar]
  21. Hajdú P., Schmidt D., Bomm M., Hack L., Keller A. Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine. Arzneimittelforschung. 1984;34(10B):1431–1435. [PubMed] [Google Scholar]
  22. Hall J. E., Coleman T. G., Guyton A. C., Kastner P. R., Granger J. P. Control of glomerular filtration rate by circulating angiotensin II. Am J Physiol. 1981 Sep;241(3):R190–R197. doi: 10.1152/ajpregu.1981.241.3.R190. [DOI] [PubMed] [Google Scholar]
  23. Halushka P. V., Margolius H. S., Allen H., Conradi E. C. Urinary excretion of prostaglandin E like material and kallikrein: effects of furosemide. Prostaglandins. 1979 Sep;18(3):359–368. doi: 10.1016/s0090-6980(79)80054-4. [DOI] [PubMed] [Google Scholar]
  24. Hollenberg N. K., Adams D. F., Mendell P., Abrams H. L., Merrill J. P. Renal vascular responses to dopamine: haemodynamic and angiographic observations in normal man. Clin Sci Mol Med. 1973 Dec;45(6):733–742. doi: 10.1042/cs0450733. [DOI] [PubMed] [Google Scholar]
  25. Israel R., O'Mara V., Austin B., Bellucci A., Meyer B. R. Metoclopramide decreases renal plasma flow. Clin Pharmacol Ther. 1986 Mar;39(3):261–264. doi: 10.1038/clpt.1986.36. [DOI] [PubMed] [Google Scholar]
  26. Jeffrey R. F., Macdonald T. M., Rutter M., Freestone S., Brown J., Samson R. R., Lee M. R. The effect of intravenous frusemide on urine dopamine in normal volunteers: studies with indomethacin and carbidopa. Clin Sci (Lond) 1987 Aug;73(2):151–157. doi: 10.1042/cs0730151. [DOI] [PubMed] [Google Scholar]
  27. Johnston G. D., Nicholls D. P., Leahey W. J., Finch M. B. The effects of captopril on the acute vascular responses to frusemide in man. Clin Sci (Lond) 1983 Oct;65(4):359–363. doi: 10.1042/cs0650359. [DOI] [PubMed] [Google Scholar]
  28. Johnston G. D., Nicholls D. P., Leahey W. J. The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmacol. 1984 Jul;18(1):75–81. doi: 10.1111/j.1365-2125.1984.tb05024.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. MCDONALD R. H., Jr, GOLDBERG L. I., MCNAY J. L., TUTTLE E. P., Jr EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW. J Clin Invest. 1964 Jun;43:1116–1124. doi: 10.1172/JCI104996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. MacDonald T. M., Jeffrey R. F., Freestone S., Lee M. R. (+)-sulpiride antagonises the renal effects of gamma-L-glutamyl-L-dopa in man. Br J Clin Pharmacol. 1988 Feb;25(2):203–212. doi: 10.1111/j.1365-2125.1988.tb03292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mackay I. G., Muir A. L., Watson M. L. Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man. Br J Clin Pharmacol. 1984 May;17(5):513–519. doi: 10.1111/j.1365-2125.1984.tb02383.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Manabe R., Honda M., Hatano M. [Changes in responses of blood pressure and several hormones to infusions of angiotensin II and angiotensin III in patients with essential hypertension]. Nihon Naibunpi Gakkai Zasshi. 1984 May 20;60(5):659–671. doi: 10.1507/endocrine1927.60.5_659. [DOI] [PubMed] [Google Scholar]
  33. Manhem P. J., Ball S. G., Morton J. J., Murray G. D., Leckie B. J., Fraser R., Robertson J. I. A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man. Br J Clin Pharmacol. 1985 Jul;20(1):27–35. doi: 10.1111/j.1365-2125.1985.tb02794.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Navar L. G., Carmines P. K., Huang W. C., Mitchell K. D. The tubular effects of angiotensin II. Kidney Int Suppl. 1987 May;20:S81–S88. [PubMed] [Google Scholar]
  35. Oliver J. A., Sciacca R. R., Cannon P. J. Renal vasodilation by converting enzyme inhibition. Role of renal prostaglandins. Hypertension. 1983 Mar-Apr;5(2):166–171. doi: 10.1161/01.hyp.5.2.166. [DOI] [PubMed] [Google Scholar]
  36. Olsen M. E., Hall J. E., Montani J. P., Cornell J. E. Protection of preglomerular vessels from angiotensin II vasoconstriction by renal prostaglandins. J Hypertens Suppl. 1985 Dec;3(3):S255–S258. [PubMed] [Google Scholar]
  37. Puschett J. B., Goldberg M. The acute effects of furosemide on acid and electrolyte excretion in man. J Lab Clin Med. 1968 Apr;71(4):666–677. [PubMed] [Google Scholar]
  38. Smit A. J., Meijer S., Wesseling H., Donker A. J., Reitsma W. D. Effect of metoclopramide on dopamine-induced changes in renal function in healthy controls and in patients with renal disease. Clin Sci (Lond) 1988 Oct;75(4):421–428. doi: 10.1042/cs0750421. [DOI] [PubMed] [Google Scholar]
  39. Watson M. L., Jones R. L. The contribution of PGI2 to the effects of captopril in conscious dogs in differing states of sodium balance. Clin Sci (Lond) 1986 Nov;71(5):533–538. doi: 10.1042/cs0710533. [DOI] [PubMed] [Google Scholar]
  40. Watson M. L., Lambie A. T., Thom A., Ungar A. Role of prostaglandins in mediating excretion by the kidney of an intravenous infusion of sodium chloride in normal human subjects. Clin Sci (Lond) 1982 Jan;62(1):27–33. doi: 10.1042/cs0620027. [DOI] [PubMed] [Google Scholar]
  41. Wilson T. W., Loadholt C. B., Privitera P. J., Halushka P. V. Furosemide increases urine 6-keto-prostaglandin F1 alpha. Relation to natriuresis, vasodilation, and renin release. Hypertension. 1982 Sep-Oct;4(5):634–641. doi: 10.1161/01.hyp.4.5.634. [DOI] [PubMed] [Google Scholar]
  42. Witte P. U., Metzger H., Eckert H. G., Irmisch R. Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers. Arzneimittelforschung. 1984;34(10B):1448–1451. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES